STIOLTO RESPIMAT Shown an Effective Therapy For Adult COPD Patients

During the recent American College of Chest Physicians Annual Meeting (CHEST 2015) in Montreal, Canada, Boehringer Ingelheim Pharmaceuticals, Inc. presented several positive post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 clinical trials. Phase III TONADO 1&2 (NCT01431274/NCT01431287) and OTEMTO® 1&2 studies evaluated the efficacy and safety of tiotropium/olodaterol delivered via the…

Boehringer Ingelheim Announces Spiolto Respimat Availability in Europe for COPD

Boehringer Ingelheim recently announced regulatory authority approvals in the first European countries for its Spiolto Respimat (tiotropium/olodaterol) therapy. The drug is a maintenance bronchodilator treatment designed to ease symptoms in adult patients suffering from chronic obstructive pulmonary disease (COPD). Boehringer did not stipulate in its press release which European countries are…